Nasdaq:PRAX
Praxis Precision Medicines, Inc.
A clinical-stage biotech firm leveraging its PRISM platform to develop precision medicines for rare genetic diseases.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe the PRISM platform can successfully translate into approved therapies with significant orphan drug market potential. The company's strong cash position provides a runway to advance its pipeline, and successful data readouts could trigger a substantial re-rating of the equity value. A first-in-class or best-in-class therapy in a rare disease space offers high upside if regulatory hurdles are cleared.
Bear Case
The stock carries high risk due to zero revenue and massive annual cash burn of $303M, which creates an urgent need for future capital raises that may dilute existing shareholders. The lack of commercial sales history and dependence on external funding make the business model vulnerable to market conditions or regulatory delays. Investors should be wary of the accumulated deficit of $1.14B and the potential for further losses before any product generates income.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines is a clinical-stage biotechnology company focused on developing novel therapies for rare genetic diseases using its proprietary PRISM platform. The company operates primarily in the United States, targeting patients with rare genetic disorders who have limited treatment options. Key products include investigational drugs such as paxalisiran, which addresses severe genetic conditions like familial hypercholesterolemia.
Analysis
Management Discussion
Despite a significant net loss of $303.3M in 2025, the company successfully managed its cash position, ending with $357.7M compared to $215.8M at the beginning of the period due to substantial financing activities totaling $702.2M. Operating expenses were dominated by research and development costs of $267.1M and general and administrative expenses of $59.1M, reflecting a strategic investment phase typical for clinical-stage biotechs.
Industry Overview
The rare disease biotechnology sector is characterized by high R&D costs, small patient populations, and specialized regulatory pathways designed to accelerate access to life-saving treatments. Companies in this space often rely on grant funding or strategic partnerships until their first product reaches late-stage clinical trials or commercialization. Market dynamics favor firms with differentiated platforms that can address multiple orphan indications efficiently.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $2.4M | $8.6M | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $2.4M | $8.6M | $0 |
| Operating Expenses | $215.0M | $128.8M | $208.7M | $326.2M |
| Operating Income | $-215.0M | $-126.4M | $-200.2M | $-326.2M |
| R&D | $155.0M | $86.8M | $152.4M | $267.1M |
| G&A | $59.9M | $42.1M | $56.3M | $59.1M |
| Stock-Based Comp | $28.6M | $24.9M | $41.4M | $33.9M |
| Depreciation | $419.0K | $432.0K | $358.0K | $140.0K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $23.4M |
| Interest Income | $957.0K | — | — | — |
| Pre-Tax Income | $-215.0M | $-126.4M | $-200.2M | $-302.8M |
| Income Tax | $-957.0K | $-3.1M | $-17.3M | $471.0K |
| Continuing Ops | $-214.0M | $-123.3M | $-182.8M | $-303.3M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-214.0M | $-123.3M | $-182.8M | $-303.3M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-214.0M | $-123.3M | $-182.8M | $-303.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $110.8M | $84.9M | $404.4M | $610.9M |
| Cash & Equivalents | $61.6M | $81.3M | $215.4M | $357.3M |
| Marketable Securities | — | — | — | $242.0M |
| Prepaid Expenses | $10.4M | $3.6M | $11.8M | $11.6M |
| Other Current Assets | $38.9M | $0 | $177.2M | $0 |
| Long-Term Assets | $4.3M | $3.1M | $78.7M | $327.0M |
| PP&E (Net) | $971.0K | $588.0K | $230.0K | $147.0K |
| Operating Leases | $2.9M | $2.1M | $1.1M | $92.0K |
| LT Securities | — | — | — | $326.8M |
| Other LT Assets | $416.0K | $416.0K | $77.4M | $0 |
| Total Assets | $115.1M | $87.9M | $483.1M | $937.9M |
| Current Liabilities | $34.3M | $15.7M | $37.5M | $59.8M |
| Accounts Payable | $14.7M | $5.8M | $12.5M | $24.6M |
| Current Leases | $1.0M | $1.1M | $1.3M | $110.0K |
| Deferred Revenue | $2.8M | $1.4M | $0 | — |
| Other Current Liab | $0 | $0 | $0 | $0 |
| Long-Term Liabilities | $4.7M | $2.5M | $110.0K | $0 |
| LT Operating Leases | $2.5M | $1.4M | $110.0K | $0 |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $39.0M | $18.3M | $37.7M | $59.8M |
| Shareholders' Equity | $76.1M | $69.7M | $445.4M | $878.1M |
| Paid-In Capital | $606.9M | $723.6M | $1.28B | $2.02B |
| Retained Earnings | $-530.6M | $-653.9M | $-836.7M | $-1.14B |
| AOCI | $-173.0K | $0 | $654.0K | $563.0K |
| Total L&E | $115.1M | $87.9M | $483.1M | $937.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-214.0M | $-123.3M | $-182.8M | $-303.3M |
| Non-Cash Adjustments | $31.1M | $38.7M | $22.6M | $32.8M |
| Working Capital Changes | $-2.1M | $-26.6M | $28.5M | $21.4M |
| Cash from Operations | $-185.0M | $-111.1M | $-131.8M | $-249.1M |
| Capital Expenditures | $444.0K | $50.0K | $0 | $56.0K |
| Cash from Investing | $96.9M | $39.0M | $-248.5M | $-311.1M |
| Cash from Financing | $10.5M | $91.9M | $514.3M | $702.2M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-77.7M | $19.7M | $134.1M | $142.0M |
| Beginning Cash | $139.7M | $62.0M | $81.7M | $215.8M |
| Ending Cash | $62.0M | $81.7M | $215.8M | $357.7M |
Frequently Asked Questions
How does Praxis Precision Medicines, Inc. make money?
The company's revenue is currently derived from grant funding and collaborations focused on its core therapeutic areas, including the treatment of severe primary biliary cholangitis, familial hypercholesterolemia, and other rare metabolic disorders. Financial data indicates minimal cost of revenue and zero gross profit, consistent with a pre-revenue clinical-stage entity where cash burn is driven by research and development expenditures totaling $267.1M.
What are the main risks for PRAX?
The company faces significant risk of dilution as it burns through cash at a rate of roughly $303M annually without commercial revenue, requiring frequent equity or debt financing. There is substantial uncertainty regarding the success of its clinical trials for paxalisiran and other candidates in rare disease indications. Regulatory approval timelines are unpredictable, and failure to secure funding could materially impact operations given the lack of current product sales.
What is PRAX's competitive advantage?
The company possesses the PRISM platform, an integrated approach combining deep genetic understanding with advanced delivery technologies to create targeted therapies for rare diseases. Its extensive pipeline addresses unmet needs in orphan indications where few alternatives exist, potentially commanding premium pricing upon approval. The firm maintains a strong balance sheet with $357.3M in cash and equivalents to fund its high-burn R&D operations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.